Parkinson’s Disease - Epidemiology Forecast to 2029

Parkinsons Disease - Epidemiology Forecast to 2029

Summary

Parkinsons disease (PD) is a progressive disorder of the nervous system that affects movement by causing shaking, stiffness, and difficulty with walking, balance, and coordination (National Institute on Aging, 2017; Mayo Clinic, 2020). PD is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, as well as non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression (World Health Organization, 2020). PD is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimers disease, affecting 1-2% of individuals ages 65 years and older worldwide (Mhyre et al., 2012; Kowal et al., 2013).

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for PD in the 7MM. It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by sex, age, and HY clinical staging.

The following data describes epidemiology of PD. In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of PD from 2,434,438 cases in 2019 to 2,999,337 cases in 2029, at an AGR of 2.32% over the forecast period. Men accounted for slightly more diagnosed prevalent cases of PD than women in the 7MM, and is one of the most common chronic progressive neurodegenerative disorders in the elderly population, as PD predominantly affects older adults. These trends are reflected in GlobalDatas forecast for the diagnosed prevalent cases for the 7MM.

Scope

- The Parkinsons Disease (PD) Epidemiology Report provides an overview of the risk factors and global trends of PD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by sex and age (ages 18 years). The diagnosed prevalent cases of PD are further segmented by Hoehn and Yahr (HY) clinical staging (stages I, II, III, IV, and V), and grouped into early (equivalent to HY clinical stages I-II), moderate-advanced (equivalent to HY clinical stages III-V), and advanced (equivalent to HY clinical stages IV-V).
- The PD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Parkinsons Disease Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global PD market.
- Quantify patient populations in the global PD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PD therapeutics in each of the markets covered.
- Understand magnitude of PD population by clinical staging.

1
1.1 List of Tables
1.2 List of Figures
2 Parkinsons Disease: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for PD (2019-2029)
3.5.1 Diagnosed Prevalent Cases of PD
3.5.2 Sex-Specific Diagnosed Prevalent Cases of PD
3.5.3 Age-Specific Diagnosed Prevalent Cases of PD
3.5.4 Diagnosed Prevalent Cases of PD by HY Clinical Staging
3.5.5 Diagnosed Prevalent Cases of PD by Type
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 COVID-19 Impact
3.6.3 Limitations of the Analysis
3.6.4 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer

List Of Tables

Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities of PD

List Of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages 18 Years, 2019 and 2029
Figure 2: 7MM, Diagnosed Prevalence (%) of PD, Both Sexes, Ages 18 Years, 2019
Figure 3: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of PD
Figure 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PD Segmented by HY Clinical Staging
Figure 5: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages 18 Years, 2019
Figure 6: 7MM, Diagnosed Prevalent Cases of PD, N, by Sex, Ages 18 Years, 2019
Figure 7: 7MM, Diagnosed Prevalent Cases of PD by Age, N, Both Sexes, 2019
Figure 8: 7MM, Diagnosed Prevalent Cases of PD by HY Clinical Staging, N, Both Sexes, Ages 18 Years, 2019
Figure 9: 7MM, Diagnosed Prevalent Cases of PD by Type, N, Both Sexes, Ages 18 Years, 2019

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available